Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

March 31, 2025

Study Completion Date

May 14, 2030

Conditions

Non-small Cell Lung CancerHepatocellular CarcinomaHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

cemiplimab

Administered intravenous (IV)

DRUG

Platinum Doublet

Administered intravenous (IV)

DRUG

fianlimab

Administered IV

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY